Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07009145Phase 2Not Yet Recruiting

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Role: collaborator

NCT06242067Phase 2Recruiting

Second-line Treatment of Metastatic Colorectal Cancer

Role: collaborator

NCT03851497Completed

Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer

Role: collaborator

NCT03236636Phase 3Unknown

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Role: collaborator

NCT01407822Phase 2Unknown

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Role: collaborator

All 5 trials loaded